No clinically significant drug interactions between lenalidomide and P-glycoprotein substrates and inhibitors: results from controlled phase I studies in healthy volunteers by Nianhang. Chen et al.
1 3
Cancer Chemother Pharmacol (2014) 73:1031–1039
DOI 10.1007/s00280-014-2438-4
OrIgInal artICle
No clinically significant drug interactions between lenalidomide 
and P‑glycoprotein substrates and inhibitors: results 
from controlled phase I studies in healthy volunteers
Nianhang. Chen · Daniel Weiss · Josephine Reyes ·  
Liangang Liu · Claudia Kasserra · Xiaomin Wang ·  
Simon Zhou · Gondi Kumar · Lilia Weiss · Maria Palmisano 
received: 17 December 2013 / accepted: 5 March 2014 / Published online: 22 March 2014 
© the author(s) 2014. this article is published with open access at Springerlink.com
upon co-administration with lenalidomide. no remarkable 
safety findings were observed.
Conclusions there are no clinically significant pharma-
cokinetic interactions between lenalidomide and substrates 
or inhibitors of P-gp.
Keywords lenalidomide · Digoxin · P-glycoprotein · 
Quinidine · temsirolimus · Drug–drug interactions
Introduction
lenalidomide is an oral IMiD® immunomodulatory agent 
[1] with proven clinical efficacy and indicated in a range 
of hematological malignancies including: relapsed and/or 
refractory multiple myeloma (MM) [2, 3] in combination 
with dexamethasone; myelodysplastic syndromes associ-
ated with del(5q); [4, 5] and relapsed or refractory mantle 
cell lymphoma [6]. lenalidomide has a predictable and 
manageable tolerability profile, with minimal neurotoxic-
ity, allowing long-term administration [7]. lenalidomide is 
rapidly absorbed (>90 %) after oral administration [8], and 
the disposition is similar in healthy subjects and patients 
[9]. approximately 80 % of the administered lenalidomide 
dose is eliminated by renal excretion of the unchanged drug 
[10]. Clearance of lenalidomide is usually lower in patients 
due to compromised renal function resulting from the dis-
ease and advanced age.
P-glycoprotein (P-gp) is a 170 kDa transmembrane gly-
coprotein that functions as a biological barrier by extrud-
ing toxins and xenobiotics out of cells [11]. It is capable 
of transporting a wide array of structurally distinct com-
pounds, including up to 50 % of currently marketed drugs 
[12]. P-gp is extensively expressed in the luminal mem-
brane of the small intestine and blood–brain barrier, and 
Abstract 
Purpose lenalidomide, a weak substrate of P-glycopro-
tein (P-gp) in vitro, is an oral anticancer drug eliminated 
predominantly via renal excretion as unchanged compound. 
the role of P-gp in lenalidomide disposition and the associ-
ated clinical relevance were evaluated.
Methods two phase I, crossover studies were conducted 
in healthy volunteers. In Study 1, subjects received lena-
lidomide (10 mg × 7 days) alone or with the P-gp substrate 
digoxin (0.5 mg on Day 5). In Study 2, subjects received 
lenalidomide (a single 25 mg dose) alone, the P-gp inhibi-
tor quinidine (300–600 mg twice-daily × 5 days) plus 
lenalidomide (on Day 4), the P-gp inhibitor/substrate tem-
sirolimus (a single 25 mg dose) alone, or lenalidomide plus 
temsirolimus. Pharmacokinetic and safety data were col-
lected for lenalidomide and the co-administrated drugs.
Results there were no significant changes in the maxi-
mum concentration (Cmax) and area under the plasma 
concentration–time curve (aUC) of lenalidomide when co-
administered with quinidine, digoxin, or temsirolimus. nei-
ther the rate nor the capacity of lenalidomide renal excre-
tion was affected by quinidine or temsirolimus, in addition 
lenalidomide absorption rate and bioavailability remained 
unchanged. Furthermore, lenalidomide had no signifi-
cant effect on blood Cmax and aUC of temsirolimus and 
its active metabolite sirolimus (also a P-gp inhibitor/sub-
strate). the Cmax of digoxin was slightly higher (+14 %) 
when administered with lenalidomide versus placebo. 
there were no other changes in digoxin pharmacokinetics 
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in the apical membranes of excretory cells such as hepat-
ocytes and the renal proximal tubule epithelia [13], hence 
contributing to the absorption, metabolism, distribution, 
and elimination of many drugs.
In monolayers of llC-PK1 and MDCKII cell lines 
expressing human P-gp, lenalidomide is a weak substrate 
of P-gp, with an efflux ratio of approximately 3, compared 
with 18 for the prototypical P-gp substrate digoxin [14, 15]. 
In the P-gp expressing llC-PK1 human cell line, lenalido-
mide up to a concentration of 300 μM did not inhibit P-gp-
dependent transport of digoxin. Based on these in vitro 
findings, pharmacokinetic drug–drug interactions (DDI) 
between lenalidomide and substrates or inhibitors of P-gp 
are not anticipated to occur in vivo.
However, two recent publications have suggested anec-
dotal P-gp-mediated drug interactions in vivo, likely lead-
ing to increased lenalidomide exposure and toxicities. In an 
uncontrolled phase I dose-ranging study with MM patients 
[15], an increase in maximum drug concentration (Cmax) 
and the area under the concentration–time curve (aUC) 
of lenalidomide (25 mg/day) was observed with increas-
ing doses of temsirolimus (15–20 mg/day), a known P-gp 
inhibitor/substrate. also, an increase in Cmax and aUC of 
temsirolimus (15 mg/day) was observed with increasing 
doses of lenalidomide (15–25 mg/day). Similarly, in a case 
report [16], the lenalidomide aUC was 12-fold higher in a 
MM patient receiving both lenalidomide (10 mg/day) and 
the P-gp inhibitor itraconazole (100 mg/day) compared 
with the aUC observed in other MM patients receiving 
lenalidomide (25 mg/day) alone. However, there was no 
difference in the elimination half-life (t1/2) of lenalidomide 
with or without itraconazole (5.5 vs. 6.7 h), which, in com-
bination with the known high bioavailability of lenalido-
mide (>90 %), makes it difficult to account for a 12-fold 
increase in aUC. Furthermore, these two studies are con-
founded with lack of control groups, small sample size, and 
use of multiple co-medications.
nevertheless, the above reports raised an important 
clinical question: What is the “true” nature of the suppos-
edly P-gp-mediated DDI of lenalidomide in spite of the 
low potential of such interaction based on in vitro find-
ings and would it lead to increased toxicity? In vitro data 
have been found to underestimate the in vivo effects of 
some drugs on pharmacokinetics of P-gp substrates [12]. 
Hence, we conducted prospective, well-controlled clini-
cal studies to evaluate the effect of three P-gp probe drugs 
on the pharmacokinetics of lenalidomide, and the effect of 
lenalidomide on the pharmacokinetics of three P-gp probe 
drugs. the three probe drugs are as follows: the prototypi-
cal P-gp substrate digoxin, the well-characterized strong 
P-gp inhibitor quinidine, and the P-gp inhibitor/substrate 
temsirolimus, which was previously suggested to have 
pharmacokinetic interactions with lenalidomide [15].
Subjects and methods
Study population
Subjects were healthy male or female volunteers with a 
body mass index of 18–33 kg/m [2], aged between 18 and 
65 years, and in good health as determined by medical his-
tory, physical examination, and clinical laboratory tests; as 
well as negative for hepatitis, HIV, and no history of drug 
or alcohol abuse. Subjects who were treated with Pg-p 
inhibitor/inducers 30 days before first dose administra-
tion were excluded from enrollment. Other exclusion cri-
teria included the use of any prescribed or non-prescribed 
systemic or topical medication (including vitamin/mineral 
supplements and herbal medicines). Permitted concomitant 
medications included paracetamol, doxycycline, and bac-
trim, and any medication necessary to treat adverse events 
(aes) or medical emergencies. the studies were conducted 
in accordance with principles of good Clinical Practice 
and were approved by the appropriate institutional review 
boards in accordance with the Declaration of Helsinki. all 
subjects provided written informed consent prior to initia-
tion of study.
Study design and treatment
two phase I, single-center studies were conducted to 
evaluate the effect of digoxin (Study 1), quinidine (Study 2, 
Part 1), and temsirolimus (Study 2, Part 2).
Evaluation of lenalidomide interaction with digoxin
Study 1 was designed as a double-blind, placebo-con-
trolled, randomized, 2-period, crossover trial. Subjects 
were randomized to receive either lenalidomide 10 mg/
day for 7 days in Study Period 1 and the matching placebo 
for 7 days in Study Period 2, or to receive the same two 
treatments in the reverse order. On Day 5 of both periods, 
a single oral 0.5 mg dose of digoxin (2 × 0.25 mg) was 
administered immediately after oral ingestion of lenalido-
mide. a 10-day washout separated the study periods. On 
Day 4 of both periods, serial blood samples up to 24 h were 
collected for measurement of lenalidomide plasma concen-
trations. Following administration of digoxin, a 72-h blood 
sample was collected to determine the plasma concentra-
tions of both digoxin and lenalidomide.
Evaluations of lenalidomide interaction with quinidine
Study 2, Part 1 was designed as an open-label, fixed-
sequence, 2-period, crossover trial. In Period 1, sub-
jects received a single oral dose of 25 mg lenalido-
mide. In Period 2, subjects received 300 mg quinidine 
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sulfate (extended-release tablets) twice-daily on Day 1 
and 600 mg twice daily on Days 2–5, with a single 25 mg 
lenalidomide dose immediately following the morning 
quinidine dose on Day 4. Study periods were separated by 
a washout of 7–10 days. In both periods, serial blood sam-
ples were collected, and urine samples were pooled over 
specified intervals for up to 48-h post-lenalidomide dos-
ing to determine plasma and urine lenalidomide concen-
trations. In Period 2, serial blood samples were collected 
prior to each morning quinidine dose, and at specified 
times for 12-h post-morning quinidine dose on Day 4 to 
determine the plasma quinidine concentrations.
Evaluation of lenalidomide interactions with temsirolimus
Study 2, Part 2 was designed as an open-label, fixed-
sequence, 3-period, crossover trial. In Period 1, subjects 
received a single oral dose of 25 mg lenalidomide; in 
Period 2, subjects received a single dose of temsirolimus 
25 mg via a 30-min intravenous (IV) infusion; and in 
Period 3, subjects received both a single 25 mg oral dose 
of lenalidomide and a single 25 mg IV dose of temsiroli-
mus. Pre-treatment with IV diphenhydramine (25 mg) was 
administered 30 min prior to start of each temsirolimus 
infusion. there was a 7–10 day washout between Study 
Periods 1 and 2, and a minimum 14-day washout between 
Study Periods 2 and 3. In Periods 1 and 3, serial blood sam-
ples were collected, and urine was pooled over specified 
intervals for up to 48-h post-lenalidomide dosing to deter-
mine plasma and urine lenalidomide concentrations. In 
Study Periods 2 and 3, serial blood samples were collected 
for 168-h after start of temsirolimus infusion to determine 
concentrations of temsirolimus and its active metabolite 
sirolimus in whole blood.
Bioanalytical methodology
Concentrations of lenalidomide, quinidine, temsirolimus, 
and sirolimus in biological fluids were determined by vali-
dated liquid chromatography mass spectrometry assays. 
For analysis of lenalidomide in plasma and urine, the assay 
ranges were 5–1,000 and 100–20,000 ng/ml, respectively, 
and the details of methods were described previously [8, 
10]. For the analysis of quinidine in plasma, the assay 
range was 20–20,000 ng/ml. Quinidine and its internal 
standard, quinidine-d3, were quantitatively extracted from 
each plasma sample by protein precipitation extraction. 
For the analysis of temsirolimus and its active metabolite 
sirolimus in whole blood, the assay range was, respectively, 
0.25–125 and 0.1–50 ng/ml. Sirolimus, temsirolimus, tac-
rolimus, and [[13] C [2, 3] H7]-temsirolimus were quanti-
tatively extracted from whole blood sample by protein pre-
cipitation extraction. Concentrations of digoxin in plasma 
were determined by a validated radioimmunoassay method 
using the Becton Dickinson Digoxin Solid-Phase Compo-
nent System. the method allowed the direct measurement 
of digoxin using a digoxin-specific antibody immobilized 
on the wall of a polypropylene tube, and the assay linear 
range was 0.1–50 ng/ml.
Pharmacokinetic analysis
non-compartmental pharmacokinetic parameters were esti-
mated from drug concentration–time profiles. Major phar-
macokinetic parameters included Cmax, time to reach Cmax 
(Tmax), terminal-phase half-life (t1/2), aUC from time zero 
to the last measurable concentration (aUCt), aUC from 
time zero to infinity (aUC∞), cumulative urinary excretion 
as a percentage of administered dose (fe), and renal clear-
ance (Clr).
Statistical analysis
an analysis of variance (anOVa) was performed on the 
natural log-transformed pharmacokinetic parameters to 
estimate the percentage ratio of geometric means between 
treatments, and the 90 % confidence interval (CI) for key 
pharmacokinetic parameters. the anOVa model included 
sequence, treatment, day, and period as fixed effects and 
subject nested within sequence as a random effect for com-
parison of a digoxin pharmacokinetic parameter with and 
without lenalidomide. For evaluation of the interaction 
between lenalidomide and quinidine or temsirolimus, the 
anOVa model included treatment as a fixed effect and 
subject as a random effect for comparison of a drug phar-
macokinetic parameter with and without the interacting 
drug.
Safety analysis
Safety was evaluated throughout each study by monitoring 
aes, physical examinations, vital signs, clinical laboratory 
values, and 12-lead electrocardiogram results and was sum-
marized using descriptive statistics.
Results
Study population
a total of 50 healthy subjects were enrolled. all subjects 
had renal and hepatic functions that were within normal 
institutional limits.
In Study 1, evaluation of lenalidomide interactions with 
digoxin, 19 healthy subjects (five females and 14 males) 
were randomized with 17 subjects completing the study. 
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Of these subjects, 15 (79 %) were african american and 4 
(21 %) were white. the mean age was 37 years (range: 22–
48 years). One subject discontinued the study at the discre-
tion of the investigator for non-compliance and one subject 
voluntarily withdrew consent for study participation.
In Study 2, Part 1, evaluation of lenalidomide inter-
actions with quinidine, 14 healthy male subjects were 
enrolled, and all subjects completed the study. Of these 
subjects, 9 (64.3 %) were african american, and 5 
(35.7 %) were white. the mean age was 38 years (range: 
26–62 years).
In Study 2, Part 2 (lenalidomide interactions with tem-
sirolimus) 17 healthy male subjects were enrolled, and 11 
completed the study. Of these subjects, 10 (58.8 %) were 
african american, and 7 (41.2 %) were white. the mean 
age was 37 years (range: 22–56 years). In total 6 subjects 
did not completed the study, 4 voluntarily withdrew consent 
for study participation, 1 was lost to follow-up after Period 
1, and 1 was withdrawn due to an ae of furuncle on Day 
27 of Period 2.
effect of co-administered drugs on lenalidomide 
pharmacokinetics in plasma
the time profiles of mean plasma concentrations for lena-
lidomide were similar when administered alone or in com-
bination with digoxin (Fig. 1a), quinidine (Fig. 1b), or 
temsirolimus (Fig. 1c). Key pharmacokinetic parameters of 
lenalidomide are summarized in table 1. there was no dif-
ference in the rate of lenalidomide absorption when admin-
istered alone or in combination with any one of the inter-
acting drugs; the observed Cmax was similar and occurred 
at a median time of 0.5–1 h under all conditions. after 
reaching Cmax, lenalidomide concentrations declined in a 
Fig. 1  Mean (±standard deviation) plasma concentration–time profile of lenalidomide alone and in the presence of (a) digoxin, (b) quinidine, or 
(c) temsirolimus in healthy subjects
Table 1  Pharmacokinetic parameters of lenalidomide alone and in the presence of digoxin, quinidine, or temsirolimus
geometric mean (geometric CV %) data are presented for all parameters except for Tmax where median (range) data are presented
AUC area under the plasma concentration curve, AUCt, aUC from time zero to the last measurable concentration, AUC∞ aUC from time zero 
to infinity, CLR renal clearance, Cmax maximum observed plasma concentration; fe, cumulative urinary excretion as a percentage of administered 
dose, ND not determined, t1/2 z terminal-phase half-life, Tmax time to reach Cmax
Pharmacokinetic 
parameter
lenalidomide (10 mg) lenalidomide (25 mg) lenalidomide (25 mg)
alone (n = 17) +Digoxin (n = 17) alone (n = 14) +Quinidine (n = 14) alone (n = 17) +temsirolimus 
(n = 11)
aUCt (h·ng/ml) 396 (32.7) 386 (38.9) 1,288 (12.1) 1,127 (9.6) 1,276 (12.0) 1,366 (14.5)
aUC∞ (h ng/ml) 475 (23.2) 491 (22.2) 1,361 (12.7) 1,190 (9.8) 1,351 (11.9) 1,445 (14.5)
Cmax (ng/ml) 119 (20.2) 118 (32.8) 367 (26.3) 337 (12.3) 364 (30.0) 361 (24.8)
tmax (h) 1 (1–2) 1 (1–2) 1 (0.5–3) 1 (0.5–1.5) 0.5 (0.5–2) 1 (1–2)
t1/2 (h) 2.40 (21.0) 2.41 (17.0) 2.81 (10.1) 2.86 (12.9) 2.81 (10.5) 2.69 (9.1)
Clr (ml/min) nD nD 227 (18.3) 245 (11.3) 251 (16.4) 229 (15.6)
fe (% dose) nD nD 74.2 (11.4) 70.2 (6.6) 81.0 (10.0) 79.6 (8.0)
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similar pattern regardless of treatment. no differences were 
observed in the mean t1/2 between treatments. In statisti-
cal comparisons, the 90 % CIs for the ratio of geometric 
means between lenalidomide alone, and lenalidomide plus 
an interacting drug were completely contained within the 
limits of 80 and 125 % for Cmax and aUC of lenalidomide 
in plasma (Fig. 2a).
effect of co-administered drugs on lenalidomide 
pharmacokinetics in urine
effect of P-gp inhibition on renal excretion of lenalidomide 
was evaluated using quinidine and temsirolimus. Under all 
treatment conditions, the urinary excretion of unchanged 
lenalidomide was nearly complete by 12-h post-dose 
(Fig. 3). the mean renal clearance and mean percentage of 
unchanged lenalidomide excreted in the urine were similar 
both in the presence and in the absence of quinidine or tem-
sirolimus (table 1). Statistical tests confirmed that the 90 % 
CIs for the ratio of geometric means between lenalidomide 
alone and lenalidomide plus an interacting drug were com-
pletely contained within the limits of 80 and 125 % for 
renal clearance of lenalidomide.
effect of lenalidomide on pharmacokinetics 
of co-administered drugs in plasma or whole blood
Key pharmacokinetic parameters of digoxin, temsirolimus, 
and sirolimus are summarized in table 2.
examination of the digoxin concentration–time profiles 
showed that except for the small difference in the peak con-
centration (at 1-h post dose), the curves for lenalidomide 
Fig. 2  ratio of geometric means and associated 90 % confidence interval for systemic exposure (Cmax and aUCt) of lenalidomide (a) and inter-
acting drugs (b) when co-administered
Fig. 3  Mean (±standard devia-
tion) renal excretion-time pro-
file of lenalidomide alone and 
in the presence of (a) quinidine 
or (b) temsirolimus in healthy 
subjects
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co-administration versus placebo co-administration were 
almost superimposed, suggesting lenalidomide does not 
affect digoxin distribution and elimination (Fig. 4a). the 
observed median digoxin Tmax was identical when co-
administered with either lenalidomide or placebo (1 h; 
range 1–3 h). the 90 % CI for the ratio of geometric means 
between digoxin plus placebo and digoxin plus lenalido-
mide for aUCt (Fig. 2a) was completely contained within 
the limits of 80 and 125 %. the mean Cmax value of digoxin 
was approximately 14 % higher in a statistically signifi-
cant manner (i.e., the upper limit of the 95 % Cl exceeded 
125 %) when co-administered with lenalidomide versus 
placebo (Fig. 2b).
the mean plasma concentration–time profiles of tem-
sirolimus (Fig. 4b) or sirolimus (Fig. 4c) were almost 
identical when temsirolimus was administered alone or 
co-administered with lenalidomide. there was no differ-
ence in Tmax and terminal t1/2 of temsirolimus or sirolimus 
between treatments (table 1). the 90 % CIs for the ratio 
of geometric means between temsirolimus alone, and tem-
sirolimus plus lenalidomide were completely contained 
within the limits l of 80 and 125 % for Cmax and aUCt of 
temsirolimus (Fig. 2b).
Quinidine concentrations in plasma
Visual inspection of the mean concentration–time pro-
file suggests that the quinidine concentration approached 
steady-state on Day 4 and the mean trough concentra-
tion ranged from 1,705 to 1,844 ng/ml on Days 4–5. the 
mean Cmax [percent coefficient of variation (CV %)] was 
2,352 ng/ml (24.3 %) on Day 4.
Safety
no remarkable safety findings were observed in these studies. 
there were no deaths or serious aes. Of all reported aes, 2 
were moderate in severity (toothache and furuncle), and all 
Table 2  Pharmacokinetic parameters of digoxin, temsirolimus, and sirolimus in the absence and presence of lenalidomide
geometric mean (geometric CV %) data are presented for all parameters except for Tmax where median (range) data are presented
AUC area under the plasma concentration curve, AUCt aUC from time zero to the last measurable concentration, AUC∞ aUC from time zero to 
infinity, CLR renal clearance, Cmax maximum observed plasma concentration; fe, cumulative urinary excretion as a percentage of administered 
dose, ND not determined, t1/2 z terminal-phase half-life, Tmax time to reach Cmax
Pharmacokinetic 
Parameter
Digoxin (0.5 mg) temsirolimus (25 mg) Sirolimus
alone (n = 17) +lenalidomide 
(n = 17)






aUCt (h ng/ml) 19.1 (30.9) 20.4 (27.8) 2,666 (27.7) 2,573 (25.6) 4,583 (21.9) 4,576 (22.3)
aUC∞ (h ng/ml) 26.3 (29.0) 28.1 (23.8) 2,804 (25.8) 2,713 (22.9) 5,357 (22.1) 5,371 (23.8)
Cmax (ng/ml) 1.69 (37.6) 1.93 (33.0) 586 (35.1) 649 (19.6) 54.0 (29.0) 56.2 (30.5)
Tmax (h) 1.0 (1–3) 1.0 (1–3) 0.47 (0.25–2) 0.47 (0.25–0.5) 1.5 (1–36) 1.5 (1–24)
t1/2 (h) 32.3 (35.0) 36.8 (27.6) 15.3 (28.5) 15.2 (27.2) 59.9 (13.7) 61.2 (9.9)
Fig. 4  Mean (standard deviation) plasma concentration–time profile of (a) digoxin, (b) temsirolimus, and (c) sirolimus in the absence and pres-
ence of lenalidoimide
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others were mild in severity. the majority of the aes were 
unrelated to study drug. there was no apparent increase in 
the number of subjects reporting aes, or the number of aes 
reported, when lenalidomide was given with digoxin, quini-
dine, or temsirolimus when compared with administration of 
lenalidomide alone or with placebo.
there were no clinically significant laboratory abnor-
malities or any apparent differences in the laboratory test 
results between study drug alone (lenalidomide, digoxin, 
quinidine, or temsirolimus) and the study drug co-admin-
istered with a tested interacting drug. Consistent with the 
known Qt prolongation effect of quinidine, there was a 
trend toward increasing Qt interval values corrected for 
heart rate (Qtc) during treatment with quinidine. no differ-
ence was observed in vital signs between treatments.
Discussion
the results presented here show that co-administration of 
lenalidomide with a P-gp substrate or inhibitor has no clini-
cally significant effect on the pharmacokinetic disposition 
of either lenalidomide or the co-administered drugs. these 
results are consistent with in vitro findings demonstrating 
that lenalidomide has a very low affinity for P-gp as a sub-
strate and is not a P-gp inhibitor.
Quinidine is a well-characterized, strong P-gp inhibitor 
often used to determine if a drug is a substrate of P-gp in 
vivo. Quinidine has a high in vivo inhibition potential on 
P-gp, as suggested by a value of approximately 1 for the 
ratio of the free-drug Cmax in vivo to the inhibition con-
stant (Ki) in vitro, which is higher than most well-known, 
“strong” P-gp inhibitors such as verapamil, itraconazole, 
ketoconazole, cyclosporine, and clarithromycin [17]. Fur-
thermore, among several assessed P-gp inhibitors, quini-
dine causes the largest increase in digoxin aUC and Cmax 
in clinical studies [12]. Quinidine has also been proven to 
significantly reduce renal clearance of digoxin in humans 
[18, 19]. thus, quinidine was selected to maximize the 
likelihood of detecting a P-gp mediated drug-interaction 
with lenalidomide. Using quinidine as the probe drug, the 
data confirms that P-gp does not play a role in the phar-
macokinetic disposition of lenalidomide. the observed 
mean quinidine trough concentration (1,705 ng/ml) was 
comparable to the historical concentration (1,430 ng/ml) 
reported for significantly inhibiting renal clearance and 
increasing plasma aUC of digoxin in healthy subjects [18]. 
In addition, the estimated mean Cmax for unbound quini-
dine (approximately 1 μM, assuming 15 % of unbound 
drug) in our study, was close to the in vitro Ki (0.9 μM) 
reported for inhibiting human P-gp transporters in vitro 
[17]. thus, plasma quinidine exposure was adequate for 
inhibition of P-gp. lenalidomide mean renal clearance 
and total urinary excretion (as percentage of administered 
dose) were comparable when lenalidomide was admin-
istered alone or in combination with quinidine, demon-
strating that the rate and capacity of lenalidomide renal 
excretion were not affected by P-gp inhibition. Similarly, 
the median Tmax and the oral bioavailability (as indicated 
by percentage of dose excreted in urine) of lenalidomide 
remained unchanged when lenalidomide was co-adminis-
tered with quinidine, suggesting that the rate and extent of 
lenalidomide oral absorption were also not altered by P-gp 
inhibition. Consequently, there was no clinically relevant 
change in the plasma exposure to lenalidomide when co-
administered with quinidine.
given the lack of effect by quinidine on lenalidomide 
exposure, it is unlikely that co-administration of other com-
monly used P-gp inhibitors or substrates would cause a 
clinically significant increase in the systemic exposure to 
lenalidomide, as confirmed in our studies using digoxin or 
temsirolimus.
Digoxin is recommended by the US Food and Drug 
administration as a P-gp substrate probe to determine 
whether a drug is an inhibitor of P-gp. like lenalidomide, 
digoxin undergoes limited metabolism and is eliminated 
predominately through renal excretion of the unchanged 
drug. Due to this absence of metabolic clearance, digoxin 
pharmacokinetics shows the highest perturbation with 
effective P-gp inhibitors in vivo as reported previously 
[12]. However, except for a 14 % increase in Cmax, no 
other meaningful changes in digoxin pharmacokinetic were 
observed after multiple doses of lenalidomide.
although it was statistically significant, a 14 % increase 
in Cmax of digoxin is unlikely to be clinically relevant. the 
underlying mechanism for this minor increase in Cmax 
cannot be explained by direct inhibition of P-gp because 
lenalidomide does not inhibit digoxin transport by P-gp 
in vitro. to date, there has been no evidence in the litera-
ture of any significant toxicity due to concomitant use of 
lenalidomide and digoxin. However, because digoxin has 
a narrow therapeutic window and repeated doses of lena-
lidomide are known to cause hematological toxicities, a 
lower dose of lenalidomide (10 mg/day) was administered 
in our study to minimize any potential toxicities. Periodic 
monitoring of digoxin concentration is still recommended 
during lenalidomide therapy.
as with quinidine or digoxin, the present studies further 
demonstrate that there are no meaningful pharmacokinetic 
interactions between lenalidomide and temsirolimus. Both 
temsirolimus and its active metabolite sirolimus are sub-
strates and inhibitors of P-gp in vitro. However, the role of 
P-gp in temsirolimus deposition in vivo is considered to be 
limited, because temsirolimus is given intravenously and 
excreted minimally in urine, thereby excluding the involve-
ment of intestinal and renal P-gp. Pharmacokinetic drug 
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interactions due to P-gp inhibition are also not expected 
between temsirolimus and lenalidomide, as lenalidomide 
is not a P-gp inhibitor in vitro [14, 20]. In addition, lena-
lidomide would not affect metabolism of temsirolimus via 
CYP3a4, which is the main elimination pathway of tem-
sirolimus, because lenalidomide is not a substrate, inhibi-
tor, or inducer of CYP3a4 [21]. thus, it is intriguing that 
an increase in the exposure of both drugs was observed 
when lenalidomide was co-administered with temsirolimus 
in an uncontrolled phase I study [15]. In well-controlled 
settings, our findings are consistent with the known mecha-
nisms underlying pharmacokinetic disposition of lenalido-
mide and temsirolimus and the in vitro and in vivo correla-
tion prediction.
the conflicting outcomes noted between the results 
described here and the studies previously reported in the 
literature highlight the importance of evaluating drug–drug 
interactions under well-controlled conditions. Both studies 
were conducted in MM patients taking multiple co-medica-
tions, and with multiple comorbidities [15, 16]. In addition, 
as lenalidomide elimination is highly dependent upon renal 
function and temsirolimus elimination is highly dependent 
upon hepatic metabolism, the contribution of imbalanced 
renal or hepatic function between treatment groups to phar-
macokinetic variability should not be overlooked. Finally, 
the reported phase I study in MM patients did not collect 
lenalidomide or temsirolimus data under monotherapy and 
thus lacked a control group for comparison with the combi-
nation therapy [15]. In contrast, our studies were conducted 
in healthy subjects with a crossover design, which not only 
controls for co-medications and organ function but also 
allows each subject to serve as their own control, thereby 
reducing the impact of the inter-individual variability.
It is possible that changes induced by MM in the proxi-
mal tubules of the kidneys (i.e., toxic effect of monoclo-
nal light chain deposition) could alter the role of P-gp in 
lenalidomide clearance, thereby leading to clinically sig-
nificant drug interactions that are not seen in healthy volun-
teers. However, we have not found any obvious difference 
in lenalidomide clearance between MM patients and other 
study populations, arguing against this possibility [9, 22].
In conclusion, co-administration with substrates or 
inhibitors of P-gp had no clinically relevant effect on the 
pharmacokinetics of lenalidomide. Similarly, coadminis-
tration with lenalidomide had no clinically relevant effect 
on the pharmacokinetics of temsirolimus. although there 
was a minor increase in digoxin Cmax when co-adminis-
tered with lenalidomide, no other changes in digoxin phar-
macokinetics were observed upon the co-administration. 
Based on these results, lenalidomide can be co-admin-
istered with a P-gp inhibitor or substrate with little or no 
interaction expected.
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